Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

被引：0

作者：

Shadman, Mazyar ^{[1
,2
]}

Flinn, Ian W. ^{[3
]}

Levy, Moshe Y. ^{[4
]}

Freeman, Benjamin B. ^{[5
]}

Zhang, Ben ^{[6
]}

Burke, John M. ^{[7
]}

Cultrera, Jennifer L. ^{[8
]}

Yimer, Habte A. ^{[9
]}

Kingsley, Edwin C. ^{[10
]}

Farber, Charles M. ^{[11
]}

D'Olimpio, James ^{[12
]}

Yao, Hui ^{[13
]}

Idoine, Adam ^{[14
]}

An, Qi ^{[13
]}

Sharman, Jeff P. ^{[15
]}

机构：

[1] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[2] Univ Washington, Seattle, WA USA

[3] Tennessee Oncol, OneOncol, Nashville, TN USA

[4] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA

[5] Summit Med Grp, Florham Pk, NJ USA

[6] Minnesota Oncol Clin, Burnsville, MN USA

[7] US Oncol Res, Rocky Mt Canc Ctr, Aurora, CO USA

[8] Florida Canc Specialists & Res Inst, Leesburg, FL USA

[9] US Oncol Res, Texas Oncol Tyler, Tyler, TX USA

[10] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[11] Morristown Med Ctr, Atlantic Hematol Oncol, Morristown, NJ USA

[12] Clin Res Alliance, Westbury, NY USA

[13] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China

[14] BeiGene USA Inc, San Mateo, CA USA

[15] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-198250

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4632 / 4633

页数：2

共 50 条

[1] Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Crescenzo, Rocco
Shadman, Mazyar
Flinn, Ian W.
Kingsley, Edwin C.
Freeman, Benjamin
Levy, Moshe Y.
Holmes, Houston
Farber, Charles M.
Chaudhry, Arvind
Idoine, Adam
Zhang, Xiaoping
Cohen, Aileen
By, Kunthel
Sharman, Jeff P.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 84 - 85
[2] Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies
Shadman, Mazyar
Flinn, Ian W.
Kingsley, Edwin C.
Freeman, Benjamin B.
Levy, Moshe
Farber, Charles M.
D'Olimpio, James
Cultrera, Jennifer L.
Zhang, Ben
Crescenzo, Rocco J.
Idoine, Adam
Zhang, Xiaoping
By, Kunthel
Sharman, Jeff P.
BLOOD, 2023, 142
[3] Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies
Shadman, Mazyar
Flinn, Ian W.
Kingsley, Edwin C.
Freeman, Benjamin
Levy, Moshe Yair
Holmes, Houston
Farber, Charles M.
Chaudhry, Arvind
Crescenzo, Rocco
Idoine, Adam
Zhang, Xiaoping
Cohen, Aileen
By, Kunthel
Huang, Jane
Sharman, Jeff P.
BLOOD, 2022, 140 : 3655 - 3657
[4] Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies
Xu, Linlin
Shadman, Mazyar
Flinn, Ian W.
Levy, Moshe Y.
Porter, Ryan
Burke, John M.
Zafar, Syed F.
Cultrera, Jennifer L.
Misleh, Jamal
Kingsley, Edwin C.
Yimer, Habte A.
Freeman, Benjamin
Chaudhry, Arvind
Tumula, Praveen K.
Gandhi, Mitul D.
Crescenzo, Rocco
By, Kunthel
Cohen, Aileen
Chen, Dih Yih
Idoine, Adam
Manda, Sudhir
Sharman, Jeff P.
Ramakrishnan, Vanitha
REVISTA CHILENA DE LITERATURA, 2024, (109): : 2284 - 2289
[5] Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies
Xu, Linlin
Shadman, Mazyar
Flinn, Ian W.
Levy, Moshe Y.
Porter, Ryan
Burke, John M.
Zafar, Syed F.
Cultrera, Jennifer L.
Misleh, Jamal
Kingsley, Edwin C.
Yimer, Habte A.
Freeman, Benjamin
Chaudhry, Arvind
Tumula, Praveen K.
Gandhi, Mitul D.
Crescenzo, Rocco
By, Kunthel
Cohen, Aileen
Chen, Dih Yih
Idoine, Adam
Manda, Sudhir
Sharman, Jeff P.
Ramakrishnan, Vanitha
HAEMATOLOGICA, 2024, 109 (07) : 2284 - 2289
[6] Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study
Xu, Linlin
Shadman, Mazyar
Flinn, Ian W.
Levy, Moshe
Porter, Ryan
Burke, John M.
Zafar, Syed F.
Cultrera, Jennifer L.
Misleh, Jamal
Kingsley, Edwin C.
Yimer, Habte A.
Freeman, Benjamin B.
Chaudhry, Arvind
Tumula, Praveen K.
Gandhi, Mitul
Crescenzo, Rocco J.
By, Kunthel
Cohen, Aileen Cleary
Idoine, Adam
Manda, Sudhir
Sharman, Jeff P.
BLOOD, 2023, 142
[7] Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib
Shadman, Mazyar
Sharman, Jeff P.
Levy, Moshe Y.
Misleh, Jamal
Zafar, Syed F.
Freeman, Benjamin B.
Burke, John M.
Cultrera, Jennifer L.
Yimer, Habte A.
Chen, Dih-Yih
Zhang, Xiaoping
Cohen, Aileen
Ro, Sunhee
Huang, Jane
Flinn, Ian W.
BLOOD, 2020, 136
[8] Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib.
Shadman, Mazyar
Sharman, Jeff Porter
Levy, Moshe Y.
Porter, Ryan
Zafar, Syed Farhan
Burke, John M.
Chaudhry, Arvind
Freeman, Benjamin Bruce
Misleh, Jamal Ghazi
Yimer, Habte Aragaw
Cultrera, Jennifer L.
Guthrie, Troy H.
Kingsley, Ed
Rao, Subramanya S.
Chen, Dih-Yih
Cohen, Aileen
Feng, Shibao
Huang, Jane
Flinn, Ian
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[9] Economic analysis of zanubrutinib vs. acalabrutinib in B-cell malignancies
不详
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2024, 17 : S59 - S59
[10] A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Shadman, Mazyar
Burke, John M.
Zafar, Syed F.
Misleh, Jamal
Rao, Subramanya S.
Farber, Charles M.
Cohen, Aileen
Crescenzo, Rocco
By, Kunthel
Flinn, Ian
Sharman, Jeff
LEUKEMIA & LYMPHOMA, 2023, 64 : S66 - S66

← 1 2 3 4 5 →